社交焦虑障碍的药物治疗：最新进展

Pharmacotherapy for social anxiety disorder: an update.

作者信息

Van Ameringen Michael, Mancini Catherine, Patterson Beth, Simpson William

机构信息

Department of Psychiatry and Behavioural Neurosciences, McMaster University Medical Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.

出版信息

Isr J Psychiatry Relat Sci. 2009;46(1):53-61.

PMID:19728573

Abstract

Since the emergence of social phobia into the diagnostic nomenclature, we have seen an exponential expansion in our knowledge regarding effective treatment of this disorder. The literature clearly supports the use of SSRIs and the SNRI venlafaxine ER as first line pharmacological agents in the treatment of GSAD. In this article, treatment studies of pharmacotherapy of social phobia are summarized. Additional issues such as comparative efficacy, treatment resistance and relapse-prevention are reviewed.

摘要

自从社交恐惧症被纳入诊断术语以来，我们对这种疾病有效治疗方法的认识呈指数级增长。文献明确支持使用选择性5-羟色胺再摄取抑制剂（SSRIs）和5-羟色胺及去甲肾上腺素再摄取抑制剂（SNRI）文拉法辛缓释剂作为广泛性社交焦虑障碍（GSAD）治疗的一线药物。本文总结了社交恐惧症药物治疗的研究。还对诸如比较疗效、治疗抵抗和预防复发等其他问题进行了综述。